Drug firm Aspen has agreed a proposed £8m settlement with the competition watchdog following a probe into the supply of a life-saving treatment for thousands of patients on the NHS.
The Competition and Markets Authority (CMA) said Aspen had agreed the payment as part of a wider package following an investigation into suspected anti-competitive arrangements regarding the supply of fludrocortisone acetate 0.1mg tablets – a treatment for Addison's disease.
The CMA said it suspected competition law had been broken by Aspen paying two rivals to stay out of the market.
These arrangements left Aspen as the sole supplier of fludrocortisone to the NHS, with the ability to set prices without facing any...
Start a 30-day free trial for unlimited access to Premium articles
- Unlimited access to Premium articles
- Subscriber-only events and experiences
- Cancel any time
Free for 30 days
then only £2 per week
Save 25% with an annual subscription
Just £75 per year